Fundamental Data for DRRX

DURECT COR(NSDQ:DRRX)

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations.

# Employees: 171

Address: 2 Results Way,Cupertino,CA,USA

Phone: 408 777-1417

Fax: 408 777-3577

Website: www.durect.com

Email: webmaster@durect.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Felix Theeuwes D.Sc. (Chmn.; Chief Scientific Off.; Dir.)

James E. Brown D.V.M (Presi.; C.E.O.; Dir.)

Jean I. Liu (Sr. V.P.; Gen. Counsel; Sec.)

Paula Mendenhall Ph.D. (Exec. V.P.; Opera. & Admn.)

Su Il Yum Ph.D. (Exec. V.P.; Pharmaceutical Systems Research and De,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/8/2010

Mean EPS (Next Qtr): ($0.09)

Mean EPS (Year): ($0.36)

Mean Estimate(Long Term): $20.00

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 4

Shares Performance

Period	DRRX	Compare to S&P
YTD	-38.35 %	-48.98 %
4 Weeks	-12.19 %	-13.13 %
12 Weeks	-17.06 %	-21.81 %

Shares Information

Analyst Coverage: Y

Avg Volume: 197704

Shares Outstanding: 82M

Market Cap: $0.17B

52 Week High: $4.20

52 Week Low: $1.44

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 DRRX split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 22.22 %

EPS Growth in Last Year: 36.36 %

Sales Growth in Last Quarter: 71.79 %

Sales Growth in Last Quarter: 26.29 %

Financials

Qtr Book Value: $6.23

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 6.610